Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.

admilparant (BMS-986278) - BMS

Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF. (PubMed, BMJ Open Respir Res) - Oct 14, 2026 - No abstract available
Journal • P3 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

http://www.ncbi.nlm.nih.gov/pubmed/42869508

Aditya Patel; Aryeh Fischer; Elizabeth Cerullo; Fernando Martinez; Marlies Wijsenbeek; Michael Kreuter; Takafumi Suda; Takashi Ogura; Tamera J Corte; Toby M Maher; Vincent Cottin; Walid Elsharkawi; Yue Wang; Zuojun Xu

Oct 14, 2026